{
    "2021-06-11": [
        [
            {
                "time": "2023-10-18",
                "original_text": "智飞生物预防性微卡获批 结核防治矩阵再添重磅产品",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "预防性微卡",
                        "结核防治",
                        "重磅产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "西部证券维持智飞生物买入评级，新品获批事件点评：预防性微卡获批，完善公司结核产品矩阵",
                "features": {
                    "keywords": [
                        "西部证券",
                        "智飞生物",
                        "买入评级",
                        "预防性微卡",
                        "结核产品矩阵"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "智飞生物(300122.SZ)：母牛分枝杆菌疫苗(结核感染人群用)药品批准证明文件处于待领取状态",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "母牛分枝杆菌疫苗",
                        "结核感染",
                        "药品批准"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "智飞生物大涨5.09% 成交额31.48万元",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大涨",
                        "成交额"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "东吴证券维持智飞生物买入评级：微卡疫苗获得药监局批准，进入“代理+自主”双驱动增长新阶段",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "智飞生物",
                        "微卡疫苗",
                        "药监局批准",
                        "双驱动增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "直击智飞生物股东大会：董事长称新冠疫苗、HPV疫苗供不应求，强研发是必走之路",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "股东大会",
                        "新冠疫苗",
                        "HPV疫苗",
                        "供不应求",
                        "强研发"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "减持资金主要投向生物医药领域 减持股份",
                "features": {
                    "keywords": [
                        "减持资金",
                        "生物医药",
                        "减持股份"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}